1. Home
  2. ROIV vs FRHC Comparison

ROIV vs FRHC Comparison

Compare ROIV & FRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ROIV
  • FRHC
  • Stock Information
  • Founded
  • ROIV 2014
  • FRHC 1981
  • Country
  • ROIV United Kingdom
  • FRHC United States
  • Employees
  • ROIV N/A
  • FRHC N/A
  • Industry
  • ROIV Biotechnology: Pharmaceutical Preparations
  • FRHC Investment Bankers/Brokers/Service
  • Sector
  • ROIV Health Care
  • FRHC Finance
  • Exchange
  • ROIV Nasdaq
  • FRHC Nasdaq
  • Market Cap
  • ROIV 8.4B
  • FRHC 7.8B
  • IPO Year
  • ROIV N/A
  • FRHC N/A
  • Fundamental
  • Price
  • ROIV $10.79
  • FRHC $176.00
  • Analyst Decision
  • ROIV Buy
  • FRHC
  • Analyst Count
  • ROIV 4
  • FRHC 0
  • Target Price
  • ROIV $17.50
  • FRHC N/A
  • AVG Volume (30 Days)
  • ROIV 5.9M
  • FRHC 78.8K
  • Earning Date
  • ROIV 05-29-2025
  • FRHC 06-13-2025
  • Dividend Yield
  • ROIV N/A
  • FRHC N/A
  • EPS Growth
  • ROIV N/A
  • FRHC N/A
  • EPS
  • ROIV N/A
  • FRHC 5.36
  • Revenue
  • ROIV $122,585,000.00
  • FRHC $1,578,152,000.00
  • Revenue This Year
  • ROIV N/A
  • FRHC N/A
  • Revenue Next Year
  • ROIV N/A
  • FRHC N/A
  • P/E Ratio
  • ROIV N/A
  • FRHC $31.78
  • Revenue Growth
  • ROIV 140.04
  • FRHC 79.07
  • 52 Week Low
  • ROIV $8.73
  • FRHC $68.82
  • 52 Week High
  • ROIV $13.06
  • FRHC $164.83
  • Technical
  • Relative Strength Index (RSI)
  • ROIV 50.06
  • FRHC 80.93
  • Support Level
  • ROIV $10.58
  • FRHC $138.99
  • Resistance Level
  • ROIV $11.77
  • FRHC $157.99
  • Average True Range (ATR)
  • ROIV 0.34
  • FRHC 4.75
  • MACD
  • ROIV -0.07
  • FRHC 2.77
  • Stochastic Oscillator
  • ROIV 17.65
  • FRHC 87.81

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About FRHC Freedom Holding Corp.

Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.

Share on Social Networks: